A study of the mechanisms for antiaggregant activity of pyrrolidone derivatives in rats with chronic hyperglycemia.
In rats with chronic alloxan-induced hyperglycemia, pramiracetam and phenylpiracetam (but not piracetam) had a strong antiaggregant effect that was mediated by various mechanisms of platelet aggregation modulation. The effect of pramiracetam is mainly realized via the inhibition of thromboxane A2 metabolism, while activity of phenylpiracetam is primarily associated with a normalizing effect on function of constitutive NO synthase in platelets and vascular endothelium.
Department of Pharmacology, Clinical Pharmacology, and Pharmacoeconomics, Dnepropetrovsk Medical Academy, Ukrainian Ministry of Health, Kyiv, Ukraine, zhylyuk@ua.fm.
V I
VI
Zhilyuk
A E
AE
Levykh
V I
VI
Mamchur
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D008297:Male; D019001:Nitric Oxide Synthase / Q000378:metabolism; D010889:Piracetam; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011759:Pyrrolidines; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D011759:Pyrrolidines; D011760:Pyrrolidinones; C038438:pramiracetam; D013928:Thromboxane A2; D019001:Nitric Oxide Synthase; D010889:Piracetam